×
About 570,645 results

Levetiracetam - levetiracetam tablet, film coated-Solco Healthcare US, LLC
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd713e60-478c-43cd-b680-ff594a0b3864

Jan 8th, 2022 - Levetiracetam is indicated for the treatment of partial-onset seizures in patients 1 month of age and older (1.1) Levetiracetam is indicated for adjunctive therapy for the treatment of: •Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy (1.2) •Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilep...

Continuous-Release Anti-VEGF Device for AMD Wins FDA Approval
https://www.medpagetoday.com/ophthalmology/generalophthalmology/95225

Oct 23rd, 2021 - The FDA has approved a first-of-its kind continuous delivery system for anti-VEGF therapy for neovascular (wet) age-related macular degeneration (AMD). The Susvimo ocular implant continuously releases 100 mg/mL of ranibizumab directly to the retina over 6 months. Initial implantation and refill can be performed during an office visit with an ophthalmologist. In contrast, conventional intravitre...

Parkinsonism and cerebrospinal fluid disorders.
https://doi.org/10.1016/j.jns.2021.120019
Journal of the Neurological Sciences; Youn J, Todisco M et. al.

Oct 23rd, 2021 - Although various motor manifestations can be seen in patients with cerebrospinal fluid (CSF) disorders, such as hydrocephalus or intracranial hypotension, the clinical presentation with parkinsonism is not clearly elucidated. We searched the literature for studies describing the occurrence of parkinsonism in subjects with normal pressure hydrocephalus (NPH), obstructive hydrocephalus, and intra...

Right Ventricular-Pulmonary Arterial Coupling in Patients With HF Secondary MR: Analysi...
https://doi.org/10.1016/j.jcin.2021.07.047
JACC. Cardiovascular Interventions; Brener MI, Grayburn P et. al.

Oct 23rd, 2021 - The aim of this study was to determine the prognostic impact of right ventricular (RV)-pulmonary arterial (PA) coupling in patients with heart failure (HF) with severe secondary mitral regurgitation (SMR) enrolled in the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) trial. RV contractile function ...

Accurately Controlled Delivery of Temozolomide by Biocompatible UiO-66-NH2 Through Ultr...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517532
International Journal of Nanomedicine; Wan Z, Li C et. al.

Oct 23rd, 2021 - Glioma is the most common and malignant primary brain tumour in adults and has a dismal prognosis. Temozolomide (TMZ) is the only clinical first-line chemotherapy drug for malignant glioma up to present. Due to poor aqueous solubility and toxic effects, TMZ is still inefficient and limited for clinical glioma treatment. UiO-66-NH2 nanoparticle is a zirconium-based framework, constructed by Zr a...

Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoemboliza...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502053
Journal of Hepatocellular Carcinoma; Wu JY, Yin ZY et. al.

Oct 23rd, 2021 - Lenvatinib (LEN) combined with anti-PD-1 antibodies (PD-1) exerted promising effects on unresectable hepatocellular carcinoma (uHCC). We assessed the safety and clinical efficacy of triple therapy [LEN+PD-1+transcatheter arterial chemoembolization (TACE)] in uHCC. uHCC patients with an ECOG PS score of 0-1 and Child-Pugh class A who underwent triple therapy were included. The primary endpoint w...

Thymoma-associated autoimmune enteropathy with colonic stricture: a diagnostic and hist...
https://doi.org/10.1007/s12328-021-01531-2 10.1038/cmi.2010.74 10.3109/08916930903555935 10.1080/08880010050211420 10.1007/s00428-017-2243-7 10.1016/j.cgh.2007.05.013 10.1056/NEJMcpc1406663 10.1093/ajcp/112.6.810 10.1007/s10620-005-2666-x 10.1007/s00428-018-2304-6 10.1007/s11894-012-0276-2 10.14309/crj.0000000000000520 10.1111/j.1572-0241.2004.40039.x 10.1136/gut.50.2.206
Clinical Journal of Gastroenterology; Pieplenbosch B, de Leijer JH et. al.

Oct 23rd, 2021 - Thymoma-associated autoimmune enteropathy is a rare paraneoplastic syndrome that is characterized by severe chronic diarrhea, malabsorption, and specific histological findings. Because of its rarity, it is difficult to diagnose. We describe an adult patient with protracted diarrhea and weight loss that developed recurrent sepsis and progressive colonic stenosis due to thymoma-associated autoimm...

The effect of immunosuppressive therapy in patients with fibrinoid necrosis lesions in ...
https://doi.org/10.1007/s40620-021-01176-x 10.1056/NEJMra1206793 10.2215/CJN.07420716 10.1093/ndt/gfy338 10.1053/j.ajkd.2019.04.031 10.1016/j.autrev.2015.02.003 10.1159/000445759 10.1053/j.ajkd.2012.06.011 10.1016/j.humpath.2018.01.026 10.1038/ki.2009.243 10.2215/CJN.11521210 10.1016/j.kint.2017.02.003 10.1046/j.1523-1755.2001.059002682.x 10.1111/j.1440-1827.1993.tb02558.x 10.2169/internalmedicine.40.862 10.1159/000065281 10.1590/s0100-879x2004000900012 10.1007/s40620-014-0165-x 10.1053/j.ajkd.2016.11.027 10.1053/ajkd.2002.31399 10.1093/ndt/gfg081 10.2215/CJN.02500317 10.1038/ki.1991.82 10.1038/ki.1990.148
Journal of Nephrology; Guo Y, Shi S et. al.

Oct 23rd, 2021 - Fibrinoid necrosis is considered one of the active pathological lesions in IgA nephropathy. Whether patients with IgA nephropathy with fibrinoid necrosis lesions benefit from immunosuppressive therapy in terms of long-term outcomes remains uncertain. This study aimed to evaluate the response to immunosuppressive therapy in patients with fibrinoid necrosis lesions in a large cohort of patients w...

Immunoglobulin A nephropathy in pediatrics: an up-to-date.
https://doi.org/10.1111/nep.13987
Nephrology (Carlton, Vic.); Paranhos RM, de Souza Figueiredo GA et. al.

Oct 23rd, 2021 - Immunoglobulin A nephropathy is the main cause of glomerulonephritis globally and an important etiology of end-stage renal disease in children. It has been considered an autoimmune disease that can lead to the production of autoantibodies against abnormal IgA1 and formation of immune complexes. These autoantibodies and immune complexes deposit in the glomeruli, resulting in renal injury. At the...

Pediatric Discoid Lupus Erythematosus: Short report.
https://doi.org/10.1111/dth.15170
Dermatologic Therapy; Hawat T, Ballouz S et. al.

Oct 23rd, 2021 - Pediatric discoid lupus erythematosus is a rare inflammatory skin disorder. This paper aims to review all the available clinical and therapeutic data on reported cases of pediatric discoid lupus erythematosus. A systematic review of the literature was conducted using Pubmed and Embase with no limitation on publication date, sex or nationality. 32 articles were included with 201 cases, a mean ag...

High expression of DHX9 promotes the growth and metastasis of hepatocellular carcinoma.
https://doi.org/10.1002/jcla.24052
Journal of Clinical Laboratory Analysis; Shi F, Cao S et. al.

Oct 23rd, 2021 - DHX9, an NTP-dependent RNA helicase, is closely associated with the proliferation and metastasis of some tumor cells and the prognosis of patients, but its role in hepatocellular carcinoma (HCC) is not well-known. This study was performed to explore the expression and role of DHX9 in HCC. The expression of DHX9 in HCC tissues and cell lines was detected by TCGA database, qPCR, western blotting,...

Double immune reconstitution therapy: cladribine after alemtuzumab in treatment of mult...
https://doi.org/10.1111/ene.15153
European Journal of Neurology; Adamec I, Jovanović I et. al.

Oct 23rd, 2021 - Alemtuzumab, a monoclonal anti-CD52 antibody, and cladribine, a purine nucleoside analogue, are used for treatment of highly active relapsing remitting multiple sclerosis (MS). Both are administered as two short yearly courses but possess the ability to induce long-term remission labeling them as immune reconstitution therapies. Although disease activity after alemtuzumab administration is rare...

Recent Advances in Photodynamic Imaging and Therapy in Hepatobiliary Malignancies: Clin...
https://doi.org/10.3390/curroncol28050345
Current Oncology (Toronto, Ont.); Nanashima A, Hiyoshi M et. al.

Oct 23rd, 2021 - The therapeutic and diagnostic modalities of light are well known, and derivative photodynamic reactions with photosensitizers (PSs), specific wavelengths of light exposure and the existence of tissue oxygen have been developed since the 20th century. Photodynamic therapy (PDT) is an effective local treatment for cancer-specific laser ablation in malignancies of some organs, including the bile ...

Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezo...
https://doi.org/10.3390/curroncol28050352
Current Oncology (Toronto, Ont.); Eso Y, Takeda H et. al.

Oct 23rd, 2021 - Combination therapy with anti-programmed death-ligand 1 monoclonal antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab (Atezo/Bev) was approved in 2020 as a first-line treatment for unresectable hepatocellular carcinoma (HCC). Atezo/Bev therapy is relatively well tolerated; however, factors that can predict its response have not yet been reported. Thus, we aimed...

Immune Checkpoint Inhibitors for Advanced Cutaneous Squamous Cell Carcinoma: A Systemat...
https://doi.org/10.1007/s11523-021-00844-z 10.1016/j.jaad.2012.11.037 10.1111/j.1365-2133.2012.10830.x 10.1016/j.jaad.2017.08.059 10.1136/bmj.f6153 10.1016/0190-9622(92)70144-5 10.1016/S0360-3016(01)01656-X 10.1016/j.jaad.2017.07.048 10.1200/JCO.2010.34.1735 10.1002/cncr.31346 10.1097/DSS.0000000000000799 10.1097/COC.0000000000000088 10.1200/JCO.2019.37.15_suppl.e21033 10.1158/1535-7163.MCT-16-0665 10.1097/EDE.0b013e3181fe7825 10.1136/bmj.315.7109.629 10.1016/S0895-4356(01)00377-8 10.1056/NEJMoa1805131 10.1200/JCO.19.03054 10.1200/JCO.19.03357 10.1016/S1470-2045(19)30728-4 10.1136/jitc-2020-000775 10.1200/JCO.2019.37.15_suppl.e21015 10.1016/j.ejca.2020.01.008 10.1007/s11864-016-0408-2 10.1016/j.ejca.2020.07.029 10.3390/cancers13143547 10.1016/j.jgo.2021.02.026 10.1111/cup.13709 10.1186/s13073-017-0424-2 10.1007/s40265-020-01302-2 10.3747/co.27.6015 10.1200/JCO.2020.38.15_suppl.TPS10084 10.1200/JCO.2019.37.15_suppl.TPS9597 10.1093/annonc/mdz394.071 10.1016/j.ejca.2008.10.026 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 10.1136/jitc-2019-000146
Targeted Oncology; Mehta NK, Li AR et. al.

Oct 23rd, 2021 - Results of early trials led to FDA approval of immune checkpoint inhibitors (ICIs) for advanced and recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (CSCC). Updated data from these trials are pending and extent of survival outcomes is undetermined. The aim of this study was to assess the efficacy of ICIs in advanced CSCC, comprising locally advanced (LA), locoregionally advanced (LR...

Real-life isoniazid and rifampicin plasma concentrations in children: a tool for therap...
https://doi.org/10.1186/s12879-021-06764-7 10.4103/ijmr.IJMR_1961_16 10.1128/AAC.00693-15 10.1093/jac/dkv148 10.1080/17425255.2018.1416093 10.1111/apm.12590 10.1517/17425255.2016.1162785 10.1128/AAC.00756-15 10.1016/j.ijid.2014.12.001 10.1086/598192 10.1136/adc.2004.052175 10.1002/bmc.2920 10.1016/j.jpba.2007.10.025 10.1046/j.1445-5994.2003.00390.x 10.1136/adc.2004.052175 10.1159/000321045 10.1016/S0378-4347(01)00434-0 10.1093/jac/dku210 10.1016/j.ijantimicag.2017.12.004 10.1016/j.ijantimicag.2014.04.019 10.1086/598192 10.1128/AAC.05429-11 10.1371/journal.pone.0102047 10.1371/journal.pmed.1002595 10.1186/s41043-017-0132-y 10.1111/jpc.13458 10.2196/mhealth.8130 10.1186/s13063-019-3483-4 10.2196/mhealth.6837 10.3346/jkms.2020.35.e92 10.1080/02770903.2019.1635153 10.2217/pgs-2018-0166 10.1128/AAC.01833-10 10.1080/17512433.2017.1246179
BMC Infectious Diseases; Tersigni C, Boiardi G et. al.

Oct 23rd, 2021 - Low plasma levels of first-line antitubercular drugs can be counted among the main causes of poor response to antitubercular therapy, and therapeutic drug monitoring has been proposed as a method to promote tailored treatments for both child and adult patients. The main aim of the study was to evaluate serum concentrations of isoniazid (INH) and rifampicin (RIF) and to investigate reasons for s...

Impact of systemic lupus erythematosus on the 5-year survival of critically ill septic ...
https://doi.org/10.1186/s13075-021-02649-x 10.7326/M17-0102 10.1136/annrheumdis-2018-214802 10.1002/art.41577 10.1093/rheumatology/keaa188 10.1016/j.berh.2019.01.013 10.1177/0961203319877947 10.1016/j.chest.2020.03.050 10.1177/1073274820920733 10.1007/s00134-019-05718-7 10.1001/jama.2016.2691 10.1164/rccm.201510-2023OC 10.1111/imr.12499 10.1007/s00134-020-06294-x 10.1001/jama.2016.0287 10.1097/00003246-200107000-00002 10.1177/1759720X20929208 10.1016/j.healthpol.2011.08.007 10.1186/1751-0473-3-17 10.1093/rheumatology/kez103 10.1177/0961203314548884 10.1001/jama.2014.2637 10.1093/rheumatology/ken196 10.1371/journal.pone.0093846 10.1016/j.jmii.2019.10.008 10.1126/science.abd4585 10.1126/science.abd4570 10.1007/s00134-020-05941-7 10.3389/fimmu.2017.00493 10.1517/14728222.2014.863876 10.1038/nature13489 10.1371/journal.pone.0189453 10.1164/rccm.201706-1248LE 10.1016/j.jinf.2019.04.005 10.1136/ard.57.10.582 10.1186/s12879-020-4826-1 10.1056/NEJMoa1415236 10.1186/s13054-016-1497-9 10.1007/s00134-020-06151-x
Arthritis Research & Therapy; Chen HH, Chen HM et. al.

Oct 23rd, 2021 - Infectious disease is an increasing threat to patients with systemic lupus erythematosus (SLE); however, the long-term outcome in critically ill septic patients with SLE remains unclear, and we aimed to address the impact of SLE on 5-year survival in critically ill septic patients. We used the 2003-2017 nationwide data with 825,556 patients with sepsis in Taiwan. We identified lupus cases with ...

Prognostic indicators and outcomes following surgical management of metastatic cutaneou...
https://doi.org/10.1016/j.bjoms.2021.01.003
The British Journal of Oral & Maxillofacial Surgery; O'Connell JE, Saeed A et. al.

Oct 23rd, 2021 - Metastatic cutaneous SCC carries a poor prognosis with five-year survival of 25%-57%. The aim of this study is to examine the outcomes following surgery with adjuvant therapy for management of metastatic cSCC in a UK-based population. This is a retrospective review of patients with metastatic cSCC of the head and neck who underwent primary surgery at a regional center during a six-year period. ...

Is treating severe He FH so easy? A combined treatment between lipoprotein apheresis an...
https://doi.org/10.1016/j.transci.2021.103258
Transfusion and Apheresis Science : Official Journal of T... Dal Pino B, Sbrana F et. al.

Oct 23rd, 2021 - Despite advance in pharmacotherapy of lipid disorders, many heterozygous Familial Hypercholesterolemia patients do not achieve a desirable lipid target to significantly reduce the risk of atherosclerotic cardiovascular disease. The aim of the present work is to evaluate the interaction between Lipoprotein apheresis (LA) and PCSK9i in a small FH cohort in which the guidelines therapeutic target ...

Video game therapy on mobility and dual tasking in multiple sclerosis: study protocol f...
https://doi.org/10.1136/bmjopen-2021-052005
BMJ Open; Baroni A, Fregna G et. al.

Oct 23rd, 2021 - Multiple sclerosis (MS) is one of the major causes of disability in young adults and affects mobility, compromising daily living activities and participation in social life. Cognitive domain is also frequently impaired in people with MS (PwMS), particularly the capacity to perform dual-task activities. Impaired cognitive processing abilities need to be treated, and motor and cognitive aspects n...